Adial to replace CEO and CFO pending stockholder approval; annual meeting set for Sept 17

ADIAL PHARMACEUTICALS, INC.

CEO Cary Claiborne and CFO Vinay Shah to be terminated effective after 2026 annual meeting if stockholder proposals approved.
Matthew Davidson, current Chief Development Officer and board member, to become President and CEO.
New CFO to be appointed; severance payments per amended employment agreements upon release execution.
Board composition and size changes anticipated, including resignation of legacy board members.
2026 annual meeting set for Sept 17, 2026; stockholder proposal deadline Aug 23, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.